I’ll explain what Alaska’s recent tobacco bill does, why taxing nicotine substitutes matters, what federal health agencies and studies have said about nicotine pouches, how this policy clashes with quitting incentives, and why some conservatives see this as a bad move for personal freedom and public health.
There’s a simple economic rule worth remembering: what you reward, you get more of, and what you tax, you get less of. The Alaska legislature passed a bill that layers a heavy excise tax on tobacco products and expands that tax to include “nicotine substitutes,” a category that reaches beyond tobacco itself. That expansion targets nicotine pouches, products many adults use as a less harmful alternative to smoking and as a quitting aid. The result is a policy that raises the cost of stepping down from cigarettes at the very moment people need cheaper, safer options.
The bill, referred to in legislative discussion as SB 24, contains this clear language about the tax increase. “Sec. 43.50.300. Excise tax levied. An excise tax is levied on tobacco products, synthetic nicotine products, and nicotine substitutes in the state at the rate of 75 percent of the wholesale price of the tobacco products.” That wording folds non-tobacco nicotine products into the same punitive tax bucket as combustible tobacco. The policy treats a harm-reduction tool like a revenue source rather than a tool for cutting smoking rates.
Federal regulators have evaluated some nicotine pouch products and found they pose lower risks than cigarettes. “The FDA determined that the specific products receiving marketing authorization met the public health standard legally required by the 2009 Family Smoking Prevention and Tobacco Control Act. This standard considers the risks and benefits of products to the population as a whole.” That statement reflects an agency assessment focused on population-level harms and benefits. It is a technical finding, not an endorsement of nicotine use, but it does recognize reduced harm compared with cigarette smoking.
The FDA also noted differences in harmful constituents between pouches and traditional cigarettes. “Among several key considerations, the agency’s evaluation showed that, due to substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products, such as moist snuff and snus, the authorized products pose lower risk of cancer and other serious health conditions than such products. The applicant also provided evidence from a study showing that a substantial proportion of adults who use cigarette and/or smokeless tobacco products completely switched to the newly authorized nicotine pouch products.” Those findings matter because switching completely from cigarettes to a substantially lower-risk product can reduce disease burden.
Public health research has also observed patterns consistent with nicotine pouches serving as alternatives for people trying to quit. “The association of nicotine pouch use with (Smokeless tobacco) SLT use is expected given product similarities. However, to our knowledge, this is the first study to show that daily nicotine pouch use is most prevalent among adults who recently quit using another tobacco product, with the largest association, after SLT use, observed among adults who recently quit cigarettes.” That quote from a peer-reviewed journal suggests pouches are commonly used by recent quitters, though it stops short of proving causation.
Those quotes and studies underline a practical point: nicotine pouches are typically not tobacco products and they contain far lower amounts of many harmful chemicals found in cigarettes. For decades, nicotine replacement therapy has helped smokers quit, and these pouches occupy a similar harm-reduction niche. Taxing them heavily undermines a clear exit ramp from cigarette smoking by making the safer option more expensive for users on tight budgets.
Local governments in Alaska already impose additional tobacco taxes in some cities, so the new statewide levy compounds an existing patchwork of costs for consumers. The legislature’s choice to include “nicotine substitutes” in the tax base appears to be a blunt tool that ignores differences among products and their potential role in reducing smoking-related harm. It also raises questions about whether the state prefers revenue over effective public health outcomes.
From a conservative perspective, policy should preserve personal freedom and encourage practical paths to healthier choices, not punish them. High excise taxes on a product people use to quit smoking are counterproductive and paternalistic. Lawmakers who claim to care about lower smoking rates should avoid measures that make quitting more expensive and less accessible.
Governor Dunleavy and other policymakers now face a choice: veto a law that treats a harm-reduction product like another sin tax or let the policy stand and watch costs rise for Alaskans trying to quit cigarettes. The legislative move deserves scrutiny for its real-world impact on quitting incentives and individual liberty.
Add comment